TransCode Therapeutics, Inc.
RNAZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $23,532 | $23,133 | $5,648,754 | $13,842,182 |
| - Cash | $5,811 | $2,768 | $4,968 | $20,826 |
| + Debt | $38 | $451 | $0 | $0 |
| Enterprise Value | $17,759 | $20,816 | $5,643,786 | $13,821,356 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$535 | -$517 | -$99 | -$42 |
| % Margin | – | – | – | – |
| EBITDA | -$16,193 | -$17,973 | -$17,466 | -$6,706 |
| % Margin | – | – | – | – |
| Net Income | -$16,755 | -$18,546 | -$17,565 | -$6,843 |
| % Margin | – | – | – | – |
| EPS Diluted | -47.14 | -3,453.53 | -1,080 | -648 |
| % Growth | 98.6% | -219.8% | -66.7% | – |
| Operating Cash Flow | -$13,336 | -$18,075 | -$15,763 | -$5,267 |
| Capital Expenditures | -$22 | -$36 | -$101 | -$255 |
| Free Cash Flow | -$13,358 | -$18,110 | -$15,863 | -$5,522 |